- Home
- PBYI vs OVID Comparison
PBYI vs OVID Comparison
Compare PBYI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | OVID |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 365.5M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PBYI | OVID |
|---|---|---|
| Price | $7.53 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 240.2K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $27,685,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | $12.27 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $2.85 | $0.27 |
| 52 Week High | $7.90 | $3.11 |
Technical Indicators
Market Signals| Indicator | PBYI | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 65.06 |
| Support Level | $7.09 | $1.43 |
| Resistance Level | $7.90 | $3.11 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 57.14 | 89.66 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.